- Home
- APGE vs MKTX Comparison
APGE vs MKTX Comparison
Compare APGE & MKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | APGE | MKTX |
|---|---|---|
| Founded | 2022 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Bankers/Brokers/Service |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | 2023 | 2004 |
Fundamental Metrics
Financial Performance| Metric | APGE | MKTX |
|---|---|---|
| Price | $134.14 | $162.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 9 |
| Target Price | $109.67 | ★ $204.88 |
| AVG Volume (30 Days) | ★ 1.2M | 875.9K |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.94% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 2.20 |
| Revenue | N/A | ★ $397,471,000.00 |
| Revenue This Year | N/A | $10.14 |
| Revenue Next Year | N/A | $7.22 |
| P/E Ratio | ★ N/A | $74.05 |
| Revenue Growth | N/A | ★ 7.45 |
| 52 Week Low | $34.34 | $108.75 |
| 52 Week High | $134.46 | $210.05 |
Technical Indicators
Market Signals| Indicator | APGE | MKTX |
|---|---|---|
| Relative Strength Index (RSI) | 79.86 | 85.52 |
| Support Level | $80.52 | $157.38 |
| Resistance Level | N/A | $178.19 |
| Average True Range (ATR) | 0.27 | 2.91 |
| MACD | -1.62 | 5.61 |
| Stochastic Oscillator | 70.00 | 97.80 |
Price Performance
Historical ComparisonAbout APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.
About MKTX MarketAxess Holdings Inc.
Founded in 2000, MarketAxess is a leading electronic fixed-income trading platform that connects broker/dealers and institutional investors. The company is primarily focused on credit based fixed income securities with its main trading products being US investment-grade and high-yield bonds, Eurobonds, and Emerging Market corporate debt. Recently the company has expanded more aggressively into Treasuries and municipal bonds with the acquisitions of LiquidityEdge and MuniBrokers in 2019 and 2021, respectively. The company also provides pre- and post-trade services with its acquisition of Regulatory Reporting Hub from Deutsche Börse Group in 2020 adding to its product offerings.